北京时间5月15日收盘,IMRA市盈率为-17.78,IMRA市值为4亿美元

IMRA简介

IMARAInc.isaclinical-stagebiopharmaceuticalcompanydedicatedtodevelopingandcommercializingnoveltherapeuticstotreatpatientssufferingfromrareinheritedgeneticdisordersofhemoglobin,knownashemoglobinopathies.Itspipelineisbuiltonthedifferentiatedtherapeuticpotentialofitsinitialproductcandidate,IMR-687,whichisanoral,once-a-day,potentiallydisease-modifyingtreatmentforsicklecelldisease,orSCD,andb-thalassemia.IMR-687isahighlyselective,potentsmallmoleculeinhibitorofphosphodiesterase-9,orPDE9,thathasamultimodalmechanismofactionthatactsprimarilyonredbloodcells,orRBCs,andhasthepotentialtoactonwhitebloodcells,orWBCs,adhesionmediatorsandothercelltypesthatareimplicatedinthesedisorders.ItisconductingaPhase2aclinicaltrialofIMR-687inadultpatientswithSCD.Inpre-specifiedinterimanalysesfromthistrial,itobservedproofofconceptclinicalactivityandIMR-687wasreportedtobewelltolerated.Ithasrecentlycompletedenrollmentandexpecttoreporttop-linedatafromthePhase2atrialinthefourthquarterof2020.BasedonthePhase2ainterimresults,itisadvancingIMR-687andintendtoinitiateaPhase2bclinicaltrialforthetreatmentofpatientswithSCDandaPhase2bclinicaltrialforthetreatmentofpatientswithb-thalassemia,eachinthefirsthalfof2020,andexpecttoreportinterimdatafromeachoftheseplannedtrialsinthefirsthalfof2021.ItsgoalistoleverageIMR-687’sdifferentiatedmechanismofaction,itseaseofadministrationandstabledrugpropertiestopotentiallyserveabroadrangeofpatientssufferingfromhemoglobinopathiesaroundtheworld,includingthoseinunderservedregions.